Literature DB >> 19103511

Comparison of efficacy between continuous hemodiafiltration with a PMMA membrane hemofilter and a PAN membrane hemofilter in the treatment of a patient with septic acute renal failure.

Kenichi Matsuda1, Takeshi Moriguchi, Norikazu Harii, Junko Goto.   

Abstract

The aim of this study was to investigate whether PMMA-CHDF in the treatment of a patient with septic acute renal failure (septic ARF) is clinically relevant. Thirteen patients were treated with PMMA-CHDF. Thirteen patients were treated with PAN-CHDF. The urinary output significantly increased in PMMA-CHDF group following 24h of the treatment (p<0.05), whereas those did not improve in PAN-CHDF group. The 28-day survival was 84.6% in PMMA-CHDF group and 38.5% in PAN-CHDF group, respectively (p<0.05). We can assume that the cytokine modulation with PMMA-CHDF in the treatment of patients with septic ARF is clinically relevant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19103511     DOI: 10.1016/j.transci.2008.11.003

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  3 in total

1.  Continuous renal replacement therapy with a polymethyl methacrylate membrane hemofilter suppresses inflammation in patients after open-heart surgery with cardiopulmonary bypass.

Authors:  Hiroshi Mukaida; Satoshi Matsushita; Takahiro Inotani; Atsushi Nakamura; Atsushi Amano
Journal:  J Artif Organs       Date:  2018-02-05       Impact factor: 1.731

2.  Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013.

Authors:  Toshiaki Arimura; Masanori Abe; Hidetoshi Shiga; Hiroshi Katayama; Kazo Kaizu; Shigeto Oda
Journal:  J Artif Organs       Date:  2017-06-09       Impact factor: 1.731

3.  Hemoperfusion with HA380 in acute type A aortic dissection patients undergoing aortic arch operation (HPAO): a randomized, controlled, double-blind clinical trial.

Authors:  Jing Yang; Dong Ji; Yue-Qian Zhu; Yun Ren; Xun Zhang; Hong-Yu Dai; Xu Sun; Yi Zhou; Zhi-Yuan Chen; Qing-Guo Li; Hao Yao
Journal:  Trials       Date:  2020-11-23       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.